文献速递静脉血栓栓塞

静脉血栓栓塞症延展抗凝治疗:美国静脉论坛与欧洲静脉论坛调查

Extended anticoagulation for venous thromboembolism: A survey of the American Venous Forum and the European Venous Forum.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2022-05-11

该调查由美国静脉论坛研究委员会设计16题在线问卷,经邮件发放给美国静脉论坛与欧洲静脉论坛成员,共144人参与(美国静脉论坛48人占33%,欧洲静脉论坛96人占66%)。72%受访者认为无诱因静脉血栓栓塞症患者复发风险总体上超过出血风险,97%可能使用延展抗凝治疗,但实践中评估复发与出血风险的方式不一致,最常用药物依次为利伐沙班、阿哌沙班、华法林、达比加群和aspirin。作者结论认为存在不同实践模式,知识缺口部分解释了长期管理的不准确与不一致。

要点

  • 72%受访者认为无诱因静脉血栓栓塞症复发风险总体超过出血风险。
  • 97%的提供者可能使用延展抗凝治疗,但实际实践模式存在差异。
  • 超过一半的医生主观估计静脉血栓栓塞症复发和出血风险。

核心结论

  • 在静脉血栓栓塞症标准治疗之后延展抗凝治疗方面存在不同实践模式。
  • 知识上的重大缺口仍是严峻挑战,部分解释了长期静脉血栓栓塞症管理的不准确与不一致。
  • 需要设计适当的研究来评估当代最佳药物治疗下的风险分层工具、准确预测静脉血栓栓塞症复发及其长期结局,并量身定制安全有效的二级预防。

研究设计与样本

  • 美国静脉论坛研究委员会创建了一项包含16个问题的在线调查。
  • 调查通过电子邮件发放给美国静脉论坛和欧洲静脉论坛的成员。
  • 共144名执业者参与,其中美国静脉论坛成员48人(33%),欧洲静脉论坛成员96人(66%)。

主要发现

  • 大多数受访者为血管专科医生,主要认证为血管外科(70%)、血管医学或血管学(9%)、静脉疾病或静脉学(3%)。
  • 144名受访者中,72%认为无诱因静脉血栓栓塞症患者复发风险总体上超过出血风险。
  • 97%的提供者可能使用延展抗凝治疗。
  • 超过一半的执业者主观估计静脉血栓栓塞症复发和出血风险。
  • 用于二级预防的抗血栓药物按频率递减依次为利伐沙班、阿哌沙班、华法林、达比加群和aspirin。

关键数值与推荐

  • 不常规考虑延展抗凝治疗的原因包括缺乏具体临床实践指南(24%)、缺乏已报告证据(9%)、缺乏有效的静脉血栓栓塞症和/或出血风险预测计算器(8%)。
  • 12名参与者(8%)表示延展抗凝治疗对大多数静脉血栓栓塞症患者无益。
  • 10名参与者(7%)表示开具延展抗凝治疗超出其专业范围。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Extended anticoagulation therapy should always be considered after standard treatment of an unprovoked episode of venous thromboembolism (VTE). It can also be considered for selected patients with provoked VTE. However, the evidence-based protocols suggested by some clinical guidelines and risk assessment tools to guide this practice are limited and ambiguous. The goal of the present survey research was to analyze current practices in applying extended anticoagulation therapy for patients with VTE among members of the American Venous Forum (AVF) and European Venous Forum (EVF). METHODS: An online survey was created by the AVF Research Committee. The survey consisted of 16 questions to identify the country of practice, specialty, experience of the participating physicians, and their clinical practice patterns in applying extended anticoagulation therapy for VTE patients. The survey was distributed via e-mail to the members of the AVF and EVF. RESULTS: A total of 144 practitioners, 48 AVF members (33%) and 96 EVF members (66%), participated in the survey. Most of the respondents identified themselves as vascular specialists with primary certification in vascular surgery (70%), vascular medicine or angiology (9%), and venous disease or phlebology (3%). Of the 144 respondents, 72% believed that the risk of VTE recurrence will generally overweigh the risk of bleeding for patients with unprovoked VTE. Extended anticoagulation therapy might be used by 97% of providers. Different patterns in real world clinical practice were identified. More than one half of the practitioners estimated the VTE recurrence and bleeding risk subjectively. The antithrombotic drugs most commonly used for secondary prophylaxis were rivaroxaban, apixaban, warfarin, dabigatran, and aspirin, in decreasing order of frequency. Among the reasons selected for not regularly considering extended anticoagulation therapy were the lack of specific clinical practice guidelines (24%), lack of reported evidence (9%), and absence of valid VTE and/or bleeding risk prediction calculators (8%). Twelve participants (8%) stated that extended anticoagulation therapy would not be beneficial for most patients with VTE. Ten participants (7%) indicated that prescribing extended anticoagulation therapy was outside the scope of their specialty. CONCLUSIONS: Different practice patterns exist regarding extending anticoagulation therapy beyond the standard treatment for patients with VTE. Major gaps in knowledge remain a serious challenge at least partially explaining the inaccuracy and inconsistency in long-term VTE management. Appropriately designed studies are needed to evaluate risk stratification tools when contemporary best medical therapy is used, accurately predict VTE recurrence and its long-term outcomes, and tailor safe and effective secondary prophylaxis.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Shaydakov ME, Ting W, Sadek M, et al. Extended anticoagulation for venous thromboembolism: A survey of the American Venous Forum and the European Venous Forum. J Vasc Surg Venous Lymphat Disord. 2022. PMID: 35561974. doi:10.1016/j.jvsv.2022.03.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。